What are the user reviews of 0.01% Atropine Sulfate Eye Drops?

0.01% Atropine Sulfate Eye Drops (EIKANCE) is a low-concentration atropine preparation mainly used to control the progression of myopia in children and adolescents. In recent years, as the rate of myopia continues to rise, low-concentration atropine eye drops have become a hot product for the prevention and treatment of myopia due to its good safety and effectiveness. EIKANCE, as a new low-concentration atropine preparation, has received widespread attention among clinical and patient groups. Its user evaluation is mainly reflected in aspects such as efficacy, safety and medication experience. According to multiple overseas clinical studies and patient feedback, EIKANCE has shown a relatively significant effect in controlling the progression of myopia. Especially after one year or more of medication, the patient's axial growth rate has significantly slowed down, which has brought greater confidence to parents and ophthalmologists.

Users generally report that EIKANCE's low-concentration design results in relatively few side effects. The incidence of common adverse reactions such as eye irritation, light sensitivity, or blurred vision is significantly lower than that of high-concentration atropine, and it is well tolerated by patients. In addition, the eye drops have a stable formula and are highly comfortable when instilled into the eyes, which is especially important when used by children. Many parents said that their children showed no obvious symptoms of discomfort while using EIKANCE, and their children had high compliance and were able to insist on daily medication, ensuring the continuity and effect of treatment. However, some patients report mild eye discomfort or temporary accommodation impairment during initial use, but most symptoms are relieved over time.

From a professional perspective,EIKANCE’s user reviews are also supported by its scientific research background. Multiple international multi-center randomized controlled trials have confirmed that low-concentration atropine can effectively delay the progression of myopia in children with mild side effects, which makes EIKANCE have good clinical application prospects.

Reference materials:https://www.medsafe.govt.nz/profs/datasheet/e/EikanceEyeDrops.pdf